Stockscreener 앱 받기
0.00%
시간 외 거래:
Altimmune Inc 주식(ALT)의 최신 뉴스
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus
H.C. Wainwright raises Altimmune stock price target on MASH focus By Investing.com - Investing.com Canada
H.C. Wainwright raises Altimmune stock price target on MASH focus - Investing.com
HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (ALT) 2026 proxy details share and ESPP increases - Stock Titan
Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright - MarketBeat
Altimmune (ALT) Sees Price Target Raised by HC Wainwright & Co. to $25 | ALT Stock News - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
3 Explosive Stocks With High Short Interest - AOL.com
Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - MarketBeat
Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025) - GuruFocus
Altimmune (MEX:ALT1) NonCurrent Deferred Revenue : MXN2.88 Mil (As of Dec. 2025) - GuruFocus
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - MarketBeat
Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com
ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union
Altimmune Bets Big on PEMB as Phase III Nears - TipRanks
Altimmune to start late-stage trial for MASH candidate this year - MSN
Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union
Altimmune CEO Durso buys $70,790 in shares By Investing.com - Investing.com India
Altimmune CEO Durso buys $70,790 in shares - Investing.com Australia
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat
Altimmune Inc (ALT) CEO Jerome Durso Increases Stake with Recent Insider Purchase - GuruFocus
Altimmune CFO Weaver buys $17,700 in shares - Investing.com
Altimmune (NASDAQ: ALT) CFO buys 5,000 shares in open market - Stock Titan
Altimmune (NASDAQ: ALT) CEO buys 20,000 shares in open market - Stock Titan
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Can Altimmune Inc. stock deliver surprise earnings beat2026 Volume Leaders & Weekly High Return Stock Forecasts - Naître et grandir
Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
History Review: Is Altimmune Inc a speculative investment2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ALT: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial - MarketBeat
Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating - marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript - Insider Monkey
Altimmune: Q4 Earnings Insights - Sahm
William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026 - Meyka
Altimmune Q4 Earnings Call Highlights - MarketBeat
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification - GuruFocus
Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - Stocktwits
1.20%
0.06%
자본화:
|
볼륨(24시간):